Proton pump inhibitors and gastric neoplasia

Kuipers, E. J.
September 2006
Gut;Sep2006, Vol. 55 Issue 9, p1217
Academic Journal
Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission of acid peptic disorders, such as gastro-oesophageal reflux disease. Side effects with respect to function and morphology of the gastric mucosa are common. Helicobacter pylon eradication can partially prevent and reverse these effects without impairing PPI therapy for gastro-oesophageal reflux disease. This makes long term PPI treatment a safe therapy for patients with acid peptic disorders. The potential side effects of such therapy are discussed here.


Related Articles

  • Heartburn issues burnt out? Sugano, Kentaro // Journal of Gastroenterology;Nov2005, Vol. 40 Issue 11, p1080 

    The article discusses issues related to the clinical research focusing on the Helicobacter pylori (H. pylori) infection and reflux esophagitis (RE). The questions raised are: whether H. pylori eradication lead to the development of RE or the worsening of pre-existing RE; whether H. pylori...

  • Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers. Wilder-Smith, Clive; Jansson, Lennart; Röhss, Kerstin; Nauclér, Emma // Clinical Drug Investigation;2004, Vol. 24 Issue 1, p1 

    Objective: A high proportion of patients with gastro-oesophageal reflux disease experience recurrence of symptoms within a year of initial treatment. The key to preventing relapse is an effective maintenance therapy that maintains intragastric pH >4. This study was conducted to compare the...

  • Esomeprazole: A Viewpoint by Peter Katelaris. Katelaris, P. // Drugs;Aug2000, Vol. 60 Issue 2, p330 

    Reviews the antacid esomeprazole. Significance of omeprazole in the management of gastro-esophageal reflux disease; Development of the proton pump inhibitor; Comparison between esomeprazole and omeprazole; Efficacy in Helicobacter pylori eradication therapy.

  • Withdrawing PPI Therapy After Healing Esophagitis Does Not Worsen Symptoms or Cause Persistent Hypergastrinemia: Analysis of Dexlansoprazole MR Clinical Trial Data. Metz, David C; Pilmer, Betsy L; Han, Cong; Perez, M Claudia // American Journal of Gastroenterology;Nov2011, Vol. 106 Issue 11, p1953 

    OBJECTIVES:Withdrawal of proton pump inhibitors (PPIs) may induce symptoms in healthy volunteers, suggesting that discontinuing PPI therapy induces acid-peptic disease. Similar assessments in patients with documented acid-related disorders are lacking.METHODS:We performed a retrospective...

  • Esophagitis in a High H. pylori Prevalence Area: Severe Disease Is Rare but Concomitant Peptic Ulcer Is Frequent. Ponce, Julio; Calvet, Xavier; Gallach, Marta; Ponce, Marta // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: Few data are available on the prevalence of erosive and severe esophagitis in Western countries. Objective: To retrospectively determine the prevalence and the factors predicting erosive esophagitis and severe esophagitis in a large series of endoscopies in Spain. Design:...

  • A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting? Tsuji, Shingo; Kawano, Sunao // Journal of Gastroenterology;May2005, Vol. 40 Issue 5, p549 

    The article focuses on a study related to the effects of lafutidine, a new-generation histamine H2-receptor antagonist (H2RA), and rabeprazole, a proton pump inhibitor (PPI), on intragastric acidity in Helicobacter pylori-negative human volunteers. Ordinary H2RAs inhibit acid secretion with an...

  • Prompt Upper Endoscopy Is an Appropriate Initial Management in Uninvestigated Chinese Patients With Typical Reflux Symptoms. Sui Peng; Li-Shou Xiong; Ying-Lian Xiao; Jin-Kun Lin; An-Jiang Wang; Ning Zhang; Pin-Jin Hu; Min-Hu Chen // American Journal of Gastroenterology;Sep2010, Vol. 105 Issue 9, p1947 

    OBJECTIVES:We sought to investigate the prevalence of clinically significant endoscopic findings (CSEFs) in Chinese patients presenting with uninvestigated typical reflux symptoms in the absence of alarm symptoms, and to evaluate whether prompt endoscopy is an appropriate initial management in...

  • Gastric Acid-Related Diseases: Focus on Esomeprazole. Al-Judaibi, B.; Chande, N.; Dresser, G. K.; Sultan, N.; J. C. Gregor // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p439 

    Esomeprazole (S-omeprazole) is a single optical enantiomer proton-pump inhibitor (PPI) approved for the management of gastro-oesophageal reflux disease, the prevention and treatment of Non-Steroidal Anti-Inflammatory Drugs (NSAID) associated gastric ulcer disease, treatment of duodenal ulcer...

  • Formulary Management of Proton Pump Inhibitors. Byrne, M.F.; Murray, F.E. // PharmacoEconomics;1999, Vol. 16 Issue 3, p225 

    The management of dyspepsia has been radically altered by the discovery of the role of Helicobacter pylori and the advent of proton pump inhibitors (PPIs). The use of PPIs alone as antisecretory agents and as part of triple therapy regimens for H. pylori eradication accounts for a significant...


Read the Article


Sign out of this library

Other Topics